The Laboratories for Personalized Molecular Medicine (LabPMM), are the Invivoscribe® global network of clinical reference labs, located in the USA, Europe and Asia, which provide international access to harmonized molecular testing. LabPMM specializes in oncology, with an emphasis on leukemias and lymphomas. We offer an ever-expanding menu of molecular assays to support medical diagnosis, research testing, stratification & enrollment of patients in clinical trials, optimization of treatments and development of companion diagnostics (CDx). LabPMM test menu is focused on biomarkers that demonstrate clinical utility, providing data and information that is clinically actionable and critical to making informed treatment decisions. Our CE-IVD assays and bioinformatics are further developed and manufactured consistently under ISO 13485 in our FDA-registered facility, making them eligible to be submitted to worldwide regulatory authorities for registration. LabPMM is the only laboratory that offers internationally harmonized testing for a number of clinically significant biomarkers. Accordingly, test results generated in any of our laboratories in Europe, Asia, or the USA are internationally concordant and reproducible. The harmonized testing provided by LabPMM assists healthcare providers in offering optimized and consistent care for their patients, as the test results accurately and reproducibly stratify patients for international clinical trials, thus ensuring that patients receive optimal treatment, and that drugs are approved quickly. LabPMM specializes in personalized molecular testing services for oncology, including leukemia and lymphoma. We are committed to providing high quality testing in support of Personalized Molecular Medicine®. Our diagnostic and research portfolio includes a full range of hematology-oncology services, such as single gene assays for FLT3, NPM1, clonality testing of B- and T-cells, minimal residual disease (MRD) screening and comprehensive next-generation sequencing (NGS) gene panels for AML and other hematologic malignancies. Rapid turn-around times are vital to ensure that all testing results and information are in the hands of the physician so that timely treatment decisions can be made. Our turnaround times for individual gene tests are in the range of 1 to 3 days following sample receipt, while turn-around times for our NGS assays and gene panels is 5 to 14 days. Testing at LabPMM expedites and streamlines patient care and clinical trial studies, as physicians receive results more quickly. The reason is simple: all of our LabPMM sites initiate tests the day of clinical sample receipt, avoiding delays caused by batching of samples for testing. Customer support is an important aspect of our services. We provide responsive timely support both via email and telephone. We are also bound by strict privacy laws and only use secure proven methods to communicate patient-related data and results. LabPMM Testing Services 2 Worldwide experts in precision medicine and companion diagnostics (CDx) of hematological malignancies. Diagnostic and R&D testing CRO Services LabPMM offers efficient and reliable standardized tests that meet the highest quality and service standards. LabPMM Locations Available services include: CDx FLT3 NGS Gene Panels Clonality testing (IGH, IGK, TRG & TRB) MRD assays Custom assays Stratification & global enrollment of patients in clinical trials USA Europe Asia LabPMM Services Catalog 2019 | 3 2